16172-96-6

Basic information

• Product Name: 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE
• Synonyms: 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE;1-[3,5-Bis(trifluoromethyl)phenyl]piperazine 98%;1-[3,5-Bis(trifluoromethyl)phenyl]piperazine98%
• CAS NO: 16172-96-6
• Molecular Formula: C₁₂H₁₂F₆N₂
• Molecular Weight: 298.23
• Product Categories: piperazines
• Mol File: 16172-96-6.mol

Chemical Properties

• Melting Point: 105-108 °C
• Boiling Point: 301.1°C at 760 mmHg
• Flash Point: 135.9°C
• Appearance: /
• Density: 1.326g/cm³
• Vapor Pressure: 0.00107mmHg at 25°C
• Refractive Index: 1.444
• PKA: 8.79±0.10(Predicted)
• CAS DataBase Reference: 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE(16172-96-6)
• EPA Substance Registry System: 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE(16172-96-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 16172-96-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE is utilized as a compound with potential therapeutic applications, particularly in the treatment of neurological and psychiatric disorders. Its pharmacological profile is being investigated for efficacy against conditions such as schizophrenia and depression.
Used in Neurotransmitter System Studies:
In the field of neuroscience, 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE serves as a valuable tool for studying neurotransmitter systems. Its interaction with these systems can provide insights into the underlying mechanisms of various neurological conditions.
Used as a Radioligand in Brain Imaging:
1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE is also studied for its potential use as a radioligand for imaging serotonin receptors in the brain. This application can aid in visualizing and understanding the role of these receptors in both health and disease states, contributing to the development of targeted therapies.
Used in the Development of New Therapeutic Agents:
The unique chemical structure and properties of 1-(3,5-BISTRIFLUOROMETHYLPHENYL)-PIPERAZINE make it a promising candidate for the development of new therapeutic agents. Its potential role in modulating neurotransmission and receptor activity positions it as a key component in the creation of innovative treatments for a range of disorders.

InChI:InChI=1/C12H12F6N2/c13-11(14,15)8-5-9(12(16,17)18)7-10(6-8)20-3-1-19-2-4-20/h5-7,19H,1-4H2

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 328-74-5 3,5-Bis-(trifluoromethyl)aniline 
• 1121599-75-4 tert-butyl 4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxylate 
• 328-70-1 3,6-bis(trifluoromethyl)bromobenzene 
• 110-85-0 piperazine 

Downstream Products

• 1287693-63-3 C₂₁H₂₇F₆N₃O 

Relevant articles and documents

LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME

LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selecte

Ligand-based rational design, synthesis and evaluation of novel potential chemical chaperones for opsin

Inherited blinding diseases retinitis pigmentosa (RP) and a subset of Leber's congenital amaurosis (LCA) are caused by the misfolding and mistrafficking of rhodopsin molecules, which aggregate and accumulate in the endoplasmic reticulum (ER), leading to photoreceptor cell death. One potential therapeutic strategy to prevent the loss of photoreceptors in these conditions is to identify opsin-binding compounds that act as chemical chaperones for opsin, aiding its proper folding and trafficking to the outer cell membrane. Aiming to identify novel compounds with such effect, a rational ligand-based approach was applied to the structure of the visual pigment chromophore, 11-cis-retinal, and its locked analogue 11-cis-6mr-retinal. Following molecular docking studies on the main chromophore binding site of rhodopsin, 49 novel compounds were synthesized according to optimized one-to seven-step synthetic routes. These agents were evaluated for their ability to compete for the chromophore binding site of opsin, and their capacity to increase the trafficking of the P23H opsin mutant from the ER to the cell membrane. Different new molecules displayed an effect in at least one assay, acting either as chemical chaperones or as stabilizers of the 9-cis-retinal-rhodopsin complex. These compounds could provide the basis to develop novel therapeutics for RP and LCA.

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.

Synthesis and evaluation of sulfonyl piperazine LpxH inhibitors

The UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH is essential in lipid A biosynthesis and has emerged as a promising target for the development of novel antibiotics against multidrug-resistant Gram-negative pathogens. Recently, we reported the c

ω-Phthalimidoalkyl Aryl Ureas as Potent and Selective Inhibitors of Cholesterol Esterase

Cholesterol esterase (CEase), a serine hydrolase thought to be involved in atherogenesis and thus coronary heart disease, is considered as a target for inhibitor development. We investigated recombinant human and murine CEases with a new fluorometric assay in a structure–activity relationship study of a small library of ω-phthalimidoalkyl aryl ureas. The urea motif with an attached 3,5-bis(trifluoromethyl)phenyl group and the aromatic character of the ω-phthalimide residue were most important for inhibitory activity. In addition, an alkyl chain composed of three or four methylene groups, connecting the urea and phthalimide moieties, was found to be an optimal spacer for inhibitors. The so-optimized compounds 2 [1-(3,5-bis(trifluoromethyl)phenyl)-3-(3-(1,3-dioxoisoindolin-2-yl)propyl)urea] and 21 [1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-(1,3-dioxoisoindolin-2-yl)butyl)urea] exhibited dissociation constants (Ki) of 1–19 μm on the two CEases and showed either a competitive (2 on the human enzyme and 21 on the murine enzyme) or a noncompetitive mode of inhibition. Two related serine hydrolases—monoacylglycerol lipase and fatty acid amide hydrolase—were inhibited by ω-phthalimidoalkyl aryl ureas to a lesser extent.

4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)- N -(4-methoxypyridin-2-yl) piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth

4′-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.

A general and convenient synthesis of N-aryl piperazines

A general and convenient synthesis of N-aryl piperazines from bis(2-chloroethyl)amine hydrochloride and a broad range of anilines in diethylene glycol monomethyl ether is described.